Genelux GNLX
NASDAQ GNLX
$1.98 -0.09 (-4.35%)
At close: Oct 22, 2026 · 4:00 PM EDT

Genelux (GNLX) Cash & Equivalents (2022 - 2026)

Updated

Genelux's Cash & Equivalents came in at $9.27 million for Q1 2026, up 73.9% from the prior quarter.

Analysis

Genelux (GNLX) Cash & Equivalents (2022 - 2026) Analysis & Trends

At the end of FY2025, Genelux's Cash & Equivalents was $5.33 million, down 37.7% from FY2024.

  • Cash & Equivalents carries a three-year compound annual growth rate of 137.7% (FY2022 to FY2025).
  • Going back by year, Cash & Equivalents was $8.57 million in FY2024 (-9.1%), $9.42 million in FY2023 and $397,000 in FY2022.
  • The Q1 2026 figure represents the highest quarterly Cash & Equivalents since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 16.91 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 6.57 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 4.90 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 3.18 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 976.00 Mn
10 Genelux 88.78 Mn 27.06 Mn - 9.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 9.27 Mn
Dec 31, 2025 5.33 Mn
Jun 30, 2025 6.55 Mn
Dec 31, 2024 8.57 Mn
Sep 30, 2024 6.10 Mn
Jun 30, 2024 7.86 Mn
Mar 31, 2024 4.06 Mn
Dec 31, 2023 9.42 Mn
Sep 30, 2023 29.87 Mn
Dec 31, 2022 397,000.00
API Access

Genelux Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GNLX&period=max&api_key=YOUR_API_KEY